Important Facts About Vaccines

Flu Vaccine

Getting the vaccine can not only keep you from getting sick with the flu, but you may also be protecting vulnerable people around you. Such as babies, young children, older adults and people with certain chronic health conditions that make them ineligible for the flu vaccine.

For our IBD patients, Dr. Higgins recommends:

- Get the shot, not the nasal inhalant
- Best to get between September 1st and January 1st

Shingles Vaccine

Shingrix is the new and improved vaccine for shingles that is given in a series of two shots. This is not a live vaccine, which means it is safe for our patients who are receiving immunosuppressant drugs. This is an across the board recommendation for all of our IBD patients who had the chicken pox more than 30 years ago. It is considered to be highly effective!

These are in high demand around the university and may be difficult to get directly from your IBD physician, if this is the case, the CVS minute clinics have a large supply and can get you in and out quickly.

Full disclosure: Your shoulder will be a bit achy after this one and you are likely to be a little tired the next day. A fair trade if you ask anyone who’s dealt with shingles!
Currently Enrolling Clinical Trials

**Ulcerative Colitis**

**ABT494—Upadacitinib**

*Oral tablet*
This is a phase 2b/3 study for patients with moderate to severe Ulcerative Colitis to evaluate the safety and effectiveness of a new medication targeting JAK1.

**BBT-401**

*Oral tablet*
This is a phase 2b study for patients with moderate to severe Ulcerative Colitis to evaluate the safety and effectiveness of a new pellino-1 inhibitor.

**ECO-RESET**

*Oral capsule*
This is a phase 2b study for patients with active, mild to moderate Ulcerative Colitis to evaluate the safety and effectiveness of a new medication that will introduce healthy bacteria to the gut without suppressing the immune system.

**Crohn’s Disease**

**M16-006—Risakunumab**

*IV Induction / Subcutaneous injections for maintenance*
This is a phase 3 study to evaluate the safety and efficacy of Risakunumab in subjects with moderate to severe Crohn’s Disease.

**ABT494 — Upadacitinib**

*Oral tablet*
This is a phase 3 study to evaluate the safety and efficacy of Upadacitinib in subjects with moderate to severe Crohn’s Disease. If eligible, subjects could be in the study for up to 244 weeks.

**Observational Studies**

**Biofire**: To determine if intestinal infections are associated with flares of irritable bowel syndrome with diarrhea

**Corrona Registry**: Provide information that may help with future treatment options for patients with IBD

**Databank**: Collect various samples from healthy volunteers and those with IBD

**FitBit Steroid Taper**: Track the outcomes of steroid tapers with the use of a FitBit wristband. The FitBit will monitor activity levels, sleep and heart rate in order to predict the outcomes of steroid tapers and predict future flares. Patients who are tapering off of prednisone and have Ulcerative Colitis or Crohn’s Disease are eligible to participate.

**PASS**: To learn more about long-term use and safety of Vedolizumab used in IBD treatment

**Sparc**: Identify new tests to predict who will respond to what treatment

**Target**: 5 year study for adults and pediatrics to specifically address clinical questions that remain unanswered from registration trials

**3D Printed Custom Ostomy Wafers**: To improve the quality and design of traditional ostomy wafers by 3D printing customized silicone wafers for patients. Patients with ostomies are eligible to participate.